OrganoClick

• It was resolved to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet.
• It was resolved that the accumulated result was brought forward and balanced in the new accounts according with the proposal of the Board.
• It was resolved to approve discharge from personal liability for the members of the Board of Directors and the CEO for their administration.
• It was resolved that the Board of Directors will have five ordinary board members.
• It was resolved in accordance with the nomination committee's proposal to pay a fixed fee of SEK 400.000 to the Chairman of the Board and a fixed fee of SEK 150.000 to the other ordinary members of the Board, in total a fee of SEK 1 000.000 to the Board, and that the Auditors’ fee's will be paid in accordance with current approved invoicing.
• It was resolved in accordance with the nomination committees proposal to re-elect Jan Johansson, Håkan Gustavson, Charlotte Karlberg and Chatarina Schneider and elect Johan Magnusson  as board members. In accordance with the nomination committees proposal, Jan Johansson was re-elected as Chairman of the Board. The Board also gave a big thank to the outgoing board member Malin Bugge for her contribution to the board and the company during her 4 years as a board member. 
• It was resolved to adopt the nomination procedure and election of nomination committee according to the proposal in the notice to the annual general meeting.
• It was resolved to adopt the boards proposal to authorise the Board of Directors during the period until the next annual general meeting, on one or more occasions, to resolve on a new issue of shares, stock options, or convertible bonds with or without deviation from the shareholders’ preferential rights to be paid in cash, in kind or by right of set-off. The issue may result in a total increase in the share capital by a maximum of 10% or SEK 97,950 (corresponding to 9,795,000 shares).
• It was resolved to adopt the nomination committees proposal that the payment of remuneration to the Board of Directors can be in the form of shares in the company or in cash

The CEO thereafter held a presentation were the previous years activities and the result of 2023 were presented including an outlook for 2024 (attached herein). The presentation is also published on the company's webpage.

OrganoClick AB (publ)

The Board of Directors